A LinkedIn post from KROMATID highlights that its VP of Platform, Erin Cross, contributed to the newly released third edition of the reference volume “Fluorescence In Situ Hybridization (FISH): Application Guide.” The book is described as covering modern protocols across FISH and comparative genomic hybridization, including multicolor FISH, cryptic aberration detection, nuclear architecture, epigenetic changes, single-cell methods, sequencing, and CRISPR/Cas9 applications.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that the guide is positioned as a resource for both early-stage researchers and experienced experts in the field. KROMATID links Erin Cross’s involvement to the company’s broader emphasis on innovation and community knowledge sharing in genomic structural analysis, particularly in support of safer and more reliable cell and gene therapies.
For investors, this type of scientific contribution may signal strong technical credibility and engagement with cutting-edge genomic methodologies that underpin KROMATID’s platform. While the post does not reference revenue, customers, or new commercial offerings, it may support the firm’s long-term competitive position in structural genomics and cell and gene therapy tools by reinforcing its visibility and influence in a specialized research community.